Plus Therapeutics (PSTV) Gross Profit (2016 - 2019)
Plus Therapeutics has reported Gross Profit over the past 9 years, most recently at $589000.0 for Q1 2019.
- Quarterly Gross Profit rose 287.5% to $589000.0 in Q1 2019 from the year-ago period, while the trailing twelve-month figure was $2.2 million through Mar 2019, up 425.77% year-over-year, with the annual reading at $3.0 million for FY2018, 1973.97% up from the prior year.
- Gross Profit was $589000.0 for Q1 2019 at Plus Therapeutics, down from $1.4 million in the prior quarter.
- Over five years, Gross Profit peaked at $1.4 million in Q4 2018 and troughed at -$125000.0 in Q1 2017.
- The 5-year median for Gross Profit is $264000.0 (2015), against an average of $359705.9.
- Year-over-year, Gross Profit crashed 117.7% in 2017 and then skyrocketed 4641.38% in 2018.
- A 5-year view of Gross Profit shows it stood at $765000.0 in 2015, then crashed by 31.9% to $521000.0 in 2016, then plummeted by 94.43% to $29000.0 in 2017, then skyrocketed by 4641.38% to $1.4 million in 2018, then crashed by 57.16% to $589000.0 in 2019.
- Per Business Quant, the three most recent readings for PSTV's Gross Profit are $589000.0 (Q1 2019), $1.4 million (Q4 2018), and $230000.0 (Q3 2018).